Recent Updates
Recently added Catalysts
ICUI Negative Sentiment

Otsuka ICU Medical LLC Issues Voluntary Nationwide Recall of 0.9% Sodium Chloride Injection, USP Due To a Product Mix-up with 10 mEq Potassium Chloride Injection

Key Takeaway: Otsuka ICU Medical LLC has issued a voluntary recall for a lot of 0.9% Sodium Chloride Injection due to a labeling mix-up that may result in the product containing Potassium Chloride instead. This poses significant health risks, particularly for vulnerable populations. The recall affects products distributed in the U.S. between December 2025 and June 2026, and customers are advised to quarantine the affected products and return them.

Market Sentiment Analysis

CONCERNS & RISKS

  • Potential mix-up could lead to serious health risks.
  • Inadvertent injection of potassium chloride can cause fatal outcomes.
  • Affected populations include vulnerable patients like premature infants.
  • No adverse events reported yet, but risks remain high.

Full Press Release Details

Contact: Consumers ICU Medical, Inc. 1-844-654-7780

AUSTIN, Texas, Sept. 17, 2026 /PRNewswire/ -- Otsuka ICU Medical LLC is issuing a voluntary recall for one lot of 0.9% SODIUM CHLORIDE Injection, USP, 100 mL single pack to the user level due to a potential mix-up. The affected lot of 0.9% SODIUM CHLORIDE Injection, USP (NDC: 0990-7984-23 Lot 1042188) may potentially contain the overwrap with labeling indicating it to be 0.9% SODIUM CHLORIDE Injection, USP (NDC: 0990-7984-23) but the actual product within the overwrap may be POTASSIUM CHLORIDE Inj. 10 mEq, (NDC 0990-7074-26) Lot 1035181. The issue has been identified through a customer complaint where a 10 mEq Highly Concentrated POTASSIUM CHLORIDE Injection 100 mL bag was found inside an overwrap of 0.9% SODIUM CHLORIDE Injection, USP 100 mL.
Risk Statement There is a reasonable probability that inadvertent injection of highly concentrated potassium chloride results in adverse events and potentially fatal outcomes. For populations most at risk, which include premature infants, patients on chronic parenteral nutrition, patients who have a history of cardiac arrhythmias, patients with chronic renal insufficiency, patients who have acute renal failure, and patients on potassium-sparing diuretics, there is a reasonable probability of adverse events such as neuromuscular dysfunction including muscle weakness, ascending paralysis, listlessness, vertigo, mental confusion, hypotension, cardiac dysrhythmias, or death from cardiac arrest. To date, Otsuka ICU Medical LLC has not received any reports of adverse events related to this recall.
Affected Product: The affected product lot was manufactured on 13 November 2025 and distributed in the United States between 30 December 2025 and 22 June 2026. Please note that the incorrect product being overwrapped with a Sodium Chloride overwrap contains its own label and clearly indicates it to be POTASSIUM CHLORIDE Inj. 10 mEq. The affected product information is provided in Table 1 below:

Table 1: Affected Product

NDC Number List Number Product Description Lot Number Expiration Date Configuration
0990-7984-23 07984-23 0.9% SODIUM CHLORIDE Injection, USP 1042188 31 October 2027 100 mL in flexible container

NDC

Number

List Number

Product Description

Lot Number

Expiration Date

Configuration

0990-7984-23
07984-23
0.9%
SODIUM CHLORIDE
Injection, USP
1042188
31 October 2027
100 mL
in flexible container

DESCRIPTION OF CASES BEING RECALLED:

NDC Number Barcode Number GTIN Lot Number Expiration Date Configuration
0990-7984-23 (01)30309907984231 1042188 31 October 2027 100mL in Flexible Container

NDC Number

Barcode Number GTIN

Lot Number

Expiration Date

Configuration

0990-7984-23
(01)30309907984231
1042188
31 October 2027
100mL in Flexible Container
Otsuka ICU Medical LLC is notifying its customers, including distributors, of this recall by letter and is requesting the return of all recalled products. All customers, including distributors, should check inventory locations within their institution for the affected product in Table 1, quarantine, and discontinue use.
Upon receipt of the completed response form, ICU Medical Customer Service will contact customers to coordinate a return label and instructions for product return.
For further inquiries, please contact ICU Medical using the information provided below.
ICU Medical Contact Contact Information Areas of Support
Global Complaint Management 1-(866)-216-8806 or [email protected] Reporting product complaints
Drug Safety 1-844-654-7780 or [email protected] Reporting adverse events for IV Solutions & Drugs
Medical Information 1-800-241-4002, option 6 or [email protected] Medical inquiries
Customer Care 1-(800)-258-5361 or [email protected] Product credit Return instructions
Field Action Processing [email protected] Questions about this action and response forms

ICU Medical Contact

Areas of Support

Global Complaint Management
1-(866)-216-8806 or
[email protected]
Reporting product complaints
Drug Safety
1-844-654-7780 or
[email protected]
Reporting adverse events for IV Solutions & Drugs
Medical Information
1-800-241-4002, option 6 or
[email protected]
Medical inquiries
Customer Care
1-(800)-258-5361 or
[email protected]
Product credit
Return instructions
Field Action Processing
[email protected]
Questions about this action and response forms
The U.S. Food and Drug Administration (FDA) has been notified of this action.
Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.
• Complete and submit the report Online: www.fda.gov/medwatch/report.htm
• Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

About Otsuka ICU Medical LLC

Otsuka ICU Medical LLC brings together global manufacturing strength, continuous innovation and a commitment to quality to deliver critical IV solutions for healthcare providers. With a broad portfolio of injectable, irrigation and parenteral nutrition products, the company is focused on building a resilient supply chain and advancing smarter, stronger patient care. Learn more at www.otsukaicumed.com.

Contact: Consumers ICU Medical, Inc. 1-844-654-7780

Media Contact: Harrison Richards ICU Medical, Inc. 949-366-4261 [email protected]

Frequently Asked Questions

What prompted the recall of Sodium Chloride Injection?

The recall was issued due to a labeling mix-up where Sodium Chloride may contain Potassium Chloride.

Who is at risk from the affected Sodium Chloride products?

Vulnerable populations include premature infants and patients with cardiac or renal issues.

What should customers do with the recalled products?

Customers should quarantine the affected products and return them as instructed by Otsuka.

Have there been any reported adverse events from this recall?

As of now, Otsuka has not received any reports of adverse events related to this recall.

Last updated: Sep 17, 2026